Subscribe

Ron Krawczyk, Jennifer Hamilton, Jason Bogroff, Blue Fin Group

Articles by Ron Krawczyk, Jennifer Hamilton, Jason Bogroff, Blue Fin Group

Specialty drugs are generating a new paradigm: Commercial Innovation

ByRon Krawczyk, Jennifer Hamilton, Jason Bogroff, Blue Fin Group

November 29th 2011

Specialty drug market success requires patient-focused and therapy-specific channel and services strategies

Latest Updated Articles

Specialty drugs are generating a new paradigm: Commercial Innovation
November 29th 2011

Trending on Pharmaceutical Commerce

Why the Direct Access Channel Is No Longer Optional for Pharma

Why UPS Committed $48M to Cold-Chain Cross-Dock Buildout

The RWE Problem Isn't Quality. It's Communication.

How the US Section 301 Probe Targets Germany's Drug Pricing

Payers Want Real-World Evidence. Why Aren't They Using It?